Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-lumefantrine dispersible tablet in infants and neonates under 5 kg with uncomplicated Plasmodium falciparum malaria
PACTR202004535453508Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of artemether and lumefantrine in Malaria, sponsored by Novartis. Primary endpoint: Artemether Cmax. Started Oct 2020; status: completed.
02
Drugs
artemetherlumefantrine
03
Conditions
Malaria
Beyond the preview
Go deeper on PACTR202004535453508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202004535453508.